Clinical Trials
Targeted Therapeutics Across Breast Cancer Subtypes
Sengupta et alRecent Patents on Anti-Cancer Drug Discovery

Breast cancer remains the most prevalent malignancy among women worldwide, characterized by distinct molecular subtypes defined by hormone receptor and growth factor receptor status. While the clinical introduction of targeted agents has markedly improved overall survival in hormone receptor-positive and HER2-positive disease, triple-negative breast cancer (TNBC) continues to present substantial therapeutic hurdles due to biological heterogeneity and a lack of approved targeted interventions.
A comprehensive review of evolving treatment paradigms assesses the translational utility of key therapeutic classes, including cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, PI3K/AKT/mTOR pathway modulators, histone deacetylase (HDAC) inhibitors, multi-target tyrosine kinase inhibitors, and immune checkpoint inhibitors. Despite therapeutic gains in specific cohorts, secondary and de novo drug resistance—often fueled by compensatory oncogenic signaling loops—remains a major barrier across all breast cancer subtypes. Addressing these resistance patterns necessitates precision-oncology frameworks driven by extensive molecular profiling, rational combination therapies, and adaptive clinical trial designs aimed at identifying actionable vulnerabilities, particularly within TNBC.
Key Takeaways
- Targeted therapeutic regimens significantly improve overall survival in hormone receptor-positive and HER2-positive breast cancers, whereas triple-negative breast cancer (TNBC) continues to present poor outcomes due to tumor heterogeneity and a scarcity of approved targeted options.
- Therapeutic resistance across breast cancer subtypes is predominantly mediated by compensatory signaling pathways, underscoring the necessity of molecular profiling and multi-agent combination regimens to sustain disease control.
Read the original sourceRecent Patents on Anti-Cancer Drug Discovery
